非小細胞肺癌 - 標靶治療 - KOL的見解

本報告根據來自北美和歐洲的 12 位 KOL（關鍵意見領袖）的觀點，對非小細胞肺癌 (NSCLC) 靶向治療的發展前景進行了深入分析。主要發現包括多項3 期試驗重新定義了Tagrisso 在EGFR 突變NSCLC 中的使用，Rybrevant 的使用範圍擴大到利基人群之外，儘管其毒性特徵較差，以及Enhertu 在HER2 突變NSCLC 中的使用有限但不斷增加。

本報告研究和分析了 NSCLC 市場，強調了未滿足的需求和新興市場趨勢，並全面評估了當前和未來的治療途徑。

報告涵蓋的主要品牌

企業

AbbVie，Amgen，Novartis，Lilly，Roche，AstraZeneca，Pfizer，Merck & Co.，Bristol Myers Squibb，Daiichi Sankyo，Takeda，Boehringer Ingelheim，Genmab，Merck Group，Blueprint，Merus，Johnson & Johnson，Hutchmed，Rigel Pharmaceuticals，Taiho Pharmaceutical，Xcovery，Cullinan Therapeutics，Dizal Pharmaceutical

目錄

摘要整理

現在與未來的治療流程

調查目的

EGFR，HER2抑制劑

• 已批准醫藥品
  • Tagrisso(osimertinib，AstraZeneca)
  • Rybrevant(amivantamab-vmjw，Genmab/Johnson & Johnson)，Lazcluze/Leclaza(lazertinib，Johnson & Johnson)
• 開發平台藥物品
  • Zipalertinib(Cullinan Therapeutics/Taiho Pharmaceutical)，Sunvozertinib(Dizal Pharmaceutical)，Zongertinib(Boehringer Ingelheim)，Zenocutuzumab(Merus)

抗體藥物複合體

• 已批准醫藥品
  • Enhertu(trastuzumab deruxtecan，Daiichi Sankyo/AstraZeneca)
• 開發平台藥物品
  • datopotamabuderukusutekan(Daiichi Sankyo/AstraZeneca)，Sacituzumab tirumotecan(Merck & Co.)，Patritumab deruxtecan(Daiichi Sankyo/Merck & Co.)，Telisotuzumab vedotin(AbbVie)

ALK抑制劑

• 已批准醫藥品
  • Alecensa(alectinib，Roche)，Alunbrig(brigatinib，Takeda)，Lorbrena/Lorviqua(lorlatinib，Pfizer)，Zykadia(ceritinib，Novartis)
• 開發平台藥物品
  • Ensartinib(Xcovery)

KRAS抑制劑

• 已批准醫藥品
  • Krazati(adagrasib，Bristol Myers Squibb)，Lumakras/Lumykras(sotorasib，Amgen)
• 開發平台藥物品
  • Olomorasib(Lilly)，MK-1084(默克)，jibarashibu(Roche)

MET抑制劑

• 已批准醫藥品
  • Tabrecta(capmatinib，Novartis)，Tepmetko((tepotinib，Merck Group)
• 開發平台藥物品
  • Savolitinib(AstraZeneca/HUTCHMED)

RET抑制劑

• 已批准醫藥品
  • Gavreto(pralsetinib，Rigel Pharmaceuticals/Blueprint Medicines)，Retevmo/Retsevmo(selpercatinib，Lilly)

ROS抑制劑

• 已批准醫藥品
  • Augtyro(repotrectinib，Bristol Myers Squibb)

BRAF抑制劑

• 已批准醫藥品
  • Braftovi(encorafenib，Pfizer)，Mektovi(binimetinib，Pfizer)，Tafinlar(dabrafenib，Novartis)，Mekinist(trametinib，Novartis)

其他的作用機制

• 已批准醫藥品
  • Xalkori(crizotinib，Pfizer)

未來的治療趨勢

• 重要的見解的摘要

附錄

KOL的快報

This report provides an in-depth analysis of the evolving landscape of targeted therapies for non-small cell lung cancer (NSCLC), based on insights from 12 key opinion leaders (KOLs) from North America and Europe. Key findings include the redefinition of Tagrisso's use in EGFR-mutated NSCLC through multiple Phase III studies, the expansion of Rybrevant's application beyond niche populations despite its challenging toxicity profile, and the limited but growing uptake of Enhertu in HER2 mutant NSCLC. The report offers a comprehensive review of current and future treatment pathways, addressing unmet needs and emerging trends in the NSCLC market.

Key brands covered in this report:

Key questions answered:

• How is the use of Tagrisso expected to evolve in the treatment of EGFRm NSCLC?
• What are the potential therapies for second-line treatment in patients resistant to third-generation EGFR-TKIs?
• How will Rybrevant's use change with new data and regulatory approvals?
• What impact will the approval of Enhertu for HER2-mutant NSCLC have on its uptake?
• Can pipeline HER2-targeting therapies like zongertinib offer competitive advantages over existing treatments?
• How will new data from studies like CROWN and ALINA affect treatment practices for ALK-positive NSCLC?
• What are the prospects for new targeted therapies for KRAS, MET, RET, ROS1, and BRAF mutations in NSCLC?
• How confident are KOLs in the impact of ADCs currently in development on the treatment paradigm?

Companies:

AbbVie, Amgen, Novartis, Lilly, Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Daiichi Sankyo, Takeda, Boehringer Ingelheim, Genmab, Merck Group, Blueprint, Merus, Johnson & Johnson, Hutchmed, Rigel Pharmaceuticals, Taiho Pharmaceutical, Xcovery, Cullinan Therapeutics, Dizal Pharmaceutical.

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

EGFR and HER2 inhibitors

• Approved drugs
  • Tagrisso (osimertinib; AstraZeneca)
  • Rybrevant (amivantamab-vmjw; Genmab/Johnson & Johnson) and Lazcluze/Leclaza (lazertinib; Johnson & Johnson)
• Pipeline drugs
  • Zipalertinib (Cullinan Therapeutics/Taiho Pharmaceutical); Sunvozertinib (Dizal Pharmaceutical); Zongertinib (Boehringer Ingelheim); Zenocutuzumab (Merus)

Antibody-drug conjugates

• Approved drugs
  • Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca)
• Pipeline drugs
  • Datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca); Sacituzumab tirumotecan (Merck & Co.); Patritumab deruxtecan (Daiichi Sankyo/Merck & Co.); Telisotuzumab vedotin (AbbVie)

ALK inhibitors

• Approved drugs
  • Alecensa (alectinib; Roche); Alunbrig (brigatinib; Takeda); Lorbrena/Lorviqua (lorlatinib; Pfizer); Zykadia (ceritinib; Novartis)
• Pipeline drugs
  • Ensartinib (Xcovery)

KRAS inhibitors

• Approved drugs
  • Krazati (adagrasib; Bristol Myers Squibb) and Lumakras/Lumykras (sotorasib; Amgen)
• Pipeline drugs
  • Olomorasib (Lilly); MK-1084 (Merck & Co.); Divarasib (Roche)

MET inhibitors

• Approved drugs
  • Tabrecta (capmatinib; Novartis) and Tepmetko (tepotinib; Merck Group)
• Pipeline drugs
  • Savolitinib (AstraZeneca/HUTCHMED)

RET inhibitors

• Approved drugs
  • Gavreto (pralsetinib; Rigel Pharmaceuticals/Blueprint Medicines) and Retevmo/Retsevmo (selpercatinib; Lilly)

ROS inhibitors

• Approved drugs
  • Augtyro (repotrectinib; Bristol Myers Squibb)

BRAF inhibitors

• Approved drugs
  • Braftovi (encorafenib; Pfizer) and Mektovi (binimetinib; Pfizer); Tafinlar (dabrafenib; Novartis) and Mekinist (trametinib; Novartis)

Other mechanisms of action

• Approved drugs
  • Xalkori (crizotinib; Pfizer)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

KOL Bulletins